CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Active control:Healthy LivingWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug1068 Home sample collection of concerning mole with physician supervision Wiki 1.00
drug2170 SSE educational intervention Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D008545 Melanoma NIH 0.58

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0012056 Cutaneous melanoma HPO 0.58

There is one clinical trial.

Clinical Trials


1 Targeted Melanoma Detection With Skin Self-examination: Leveraging the Mammogram Encounter

The purpose of this study is to reduce melanoma mortality by improving early detection of melanoma with skin self-examination (SSE) among people who self-identify as being at risk and seek care for a concerning mole. Because women are more likely than men to perform SSE, women who are engaged in health promotion by having a recent screening mammogram are the focus of this research. Self-management of melanoma detection with SSE depends on ready access to dermatologists when a concerning mole is detected. In March 2020, the Illinois stay at home order (COVID-19) prohibited non-essential health care, including screening mammography and dermatology office-based care, and both are expected to remain limited until fall 2020. This submission explores a) the effectiveness of targeted melanoma detection (TMD) among women, who identify their risk of having a melanoma, learn to perform SSE, and perform SSE, and b) the effectiveness of adhesive patch-based home sample collection for genomic analysis to rule out melanoma in moles identified by women as concerning.

NCT04420273 Melanoma Behavioral: SSE educational intervention Other: Home sample collection of concerning mole with physician supervision Behavioral: Active control:Healthy Living
MeSH:Melanoma
HPO:Cutaneous melanoma Melanoma

Primary Outcomes

Description: Self-reported performance of SSE, a custom scale with the frequency and extent of SSE is completed in an online monthly survey

Measure: Change in SSE performance

Time: 90 days

Description: Self-reported identification of concerning mole identified by user assigning scores to the border,color and diameter of the mole. A validated scoring system is used to categorize the border, color and diameter as 1 if normal, 2 if not sure, and 3 if abnormal.The sum of the scores indicates if the mole is concerning (sum of 3= benign, stop checking the mole; sum of 4- 7 monitor the mole for change in the next month; sum of 8-9 = concerning mole make an appointment to see a physician.

Measure: Identification of concerning mole

Time: 90 days

Description: The quantity of cells obtained for genomic analysis will be assessed. The results of the genomic analysis will be validated with the pathological findings of the biopsied concerning mole. A Student t test will be performed for the null hypothesis of no difference between the genomic analysis and the pathological finding of melanoma.

Measure: Effectiveness of adhesive patch-based home sample collection for genomic analysis of concerning moles to rule-out melanoma

Time: 90 Days

Secondary Outcomes

Description: Self-reported responses to 7 items, each with a 5-point Likert scale (range 7-35) higher score= more anxiety

Measure: Change in skin self-examination anxiety

Time: 90 days

Description: Self-reported responses to 7 items, each with a 5-point Likert scale (range 7-35) higher score = greater confidence.

Measure: Change in confidence performing mole checks

Time: 90 days

Description: Electronic medical record review

Measure: Number of physician visits for concerning moles

Time: 5 months

Description: Electronic medical record review

Measure: Number of biopsies of concerning moles

Time: 5 months


Related HPO nodes (Using clinical trials)